Published in:
Open Access
01-12-2018 | Research article
Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial
Authors:
Philippe Le Corvoisier, Romain Gallet, Pierre-François Lesault, Etienne Audureau, Muriel Paul, Julien Ternacle, Saïd Ghostine, Stéphane Champagne, Raphaele Arrouasse, Dalila Bitari, Gauthier Mouillet, Jean-Luc Dubois-Randé, Alain Berdeaux, Bijan Ghaleh, Jean-François Deux, Emmanuel Teiger
Published in:
BMC Cardiovascular Disorders
|
Issue 1/2018
Login to get access
Abstract
Background
Experimental studies suggest that morphine may protect the myocardium against ischemia-reperfusion injury by activating salvage kinase pathways. The objective of this two-center, randomized, double-blind, controlled trial was to assess potential cardioprotective effects of intra-coronary morphine in patients with ST-segment elevation myocardial infarction (STEMI) referred for primary percutaneous intervention.
Methods
Ninety-one patients with STEMI were randomly assigned to intracoronary morphine (1 mg) or placebo at reperfusion of the culprit coronary artery. The primary endpoint was infarct size/left ventricular mass ratio assessed by magnetic resonance imaging on day 3–5. Secondary endpoints included the areas under the curve (AUC) for troponin T and creatine kinase over three days, left ventricular ejection fraction assessed by echocardiography on days 1 and 6, and clinical outcomes.
Results
Infarct size/left ventricular mass ratio was not significantly reduced by intracoronary morphine compared to placebo (27.2% ± 15.0% vs. 30.5% ± 10.6%, respectively, p = 0.28). Troponin T and creatine kinase AUCs were similar in the two groups. Morphine did not improve left ventricular ejection fraction on day 1 (49.7 ± 10.3% vs. 49.3 ± 9.3% with placebo, p = 0.84) or day 6 (48.5 ± 10.2% vs. 49.0 ± 8.5% with placebo, p = 0.86). The number of major adverse cardiac events, including stent thrombosis, during the one-year follow-up was similar in the two groups.
Conclusions
Intracoronary morphine at reperfusion did not significantly reduce infarct size or improve left ventricular systolic function in patients with STEMI. Presence of comorbidities in some patients may contribute to explain these results.
Trial registration
ClinicalTrials.gov,
NCT01186445 (date of registration: August 23, 2010).